With changing population demographics, the incidence of both diabetes is increasing and new improved therapies are required to treat the neovascular changes at the back of the eye.
Current therapies for diabetic eye disease require intraocular injection of large molecules. A vast majority of early-stage diabetic retinopathy patients are not treated, in a watch-and-wait pattern until their disease deteriorates, and an invasive solution is not adequate, so the market for Exonate’s small molecules as topical eye drop administration is compelling
The global cost of visual impairment due to diabetic retinopathy - Exonate’s first therapeutic target area in ophthalmology – is $129 billion, and is one of the most invested in area of ophthalmology by venture capitalists.
Finance
- April 2014 - Seed investment £400K
- Oct 2015 – 2nd stage £800K
- Nov 2016 – 3rd stage £1.5M
- Feb 2017 - Wellcome Trust SDDI £4.9M
- Jan 2020 - Janssen collaboration
Board members
- Dr Rafiq Hasan - Chairman
- Dr Catherine Beech OBE - CEO
- Professor Steven Harper - Medical Director
- Dr Chris Torrance – Chair Phoremost Ltd
- Dr John Kurek – Uniseed
- Dr Sam Fazeli - Independent Director
- Sunil Shah - Director
CAB
- Professor Lloyd Paul Aiello
- Professor Peter Campochiaro
- Professor Usha Chakravarthy
- Professor Robyn Guymer